Nucleus Genomics subway ad blitz triggers fraud allegations and a competitor lawsuit
Nov 24, 2025
Key Points
- Nucleus Genomics launched a 1,000+ subway ad blitz in New York making genetic claims like 'IQ is 50% genetic,' despite being unable to offer services in the state.
- Critics allege Nucleus uses AI-generated customer testimonials, plagiarized white papers, and AI blog posts; founder Kian responds with competitor accusations rather than substantive rebuttals.
- For a biotech company making high-stakes embryo selection claims, evasive responses to scientific critique risk customer trust and adoption, observers say.
Summary
Nucleus Genomics, an IVF and genetic optimization startup, ran a subway advertising blitz across New York City claiming "IQ is 50% genetic" and "Height is 80% genetic," paired with "Have your best baby" and "IVF done right." The campaign reportedly included over 1,000 subway car ads, 1,000+ street ads, and dozens of urban panels in SoHo. Nucleus cannot actually offer its service in New York, and the campaign was designed as rage bait to drive viral attention.
Sichuan Mala, an independent researcher, published a detailed essay alleging multiple problems with Nucleus's claims and practices. Nucleus founder Kian responded by denying all allegations and suggesting the critique was "architected by a competitor that has repeatedly published misstatements." He also alleged that Cremieux, a "race scientist," was paid by competitors to promote "nonsense" against Nucleus, and noted that Nucleus won a preliminary injunction in a lawsuit filed by a competitor.
The substantive concerns are significant. Cremieux documented that Roy Lee, founder of Cluely (an AI tool known for enabling test cheating), previously worked at Nucleus and posted grateful remarks about the company in February 2025, just months before launching his own venture. Cremieux presented this as evidence of broader fraud.
Critics claim Nucleus's customer testimonials use AI-generated imagery and may be fictitious. Nucleus has not publicly confirmed whether reviews are real or explained its use of AI-generated imagery, despite a plausible privacy defense it has not articulated. Additional documented issues include alleged AI-generated blog posts, plagiarism in Nucleus's origin white paper, contradictory terms of service, and the hiring of two employees from a competitor despite their 18-month non-competes. Nucleus argued the non-competes did not apply because the roles were not competitive, though the companies' offerings overlap directly.
Kian's response focused on accusing critics of being paid by competitors and replying with memes rather than substantive rebuttals. Will O'Brien and other observers noted that Nucleus is "doing an absolutely terrible job at responding" and making "zero points of substance" while "leaping ahead and insinuating others are jealous." For a scientific product making bold embryo selection claims, a good-faith critique demands detailed, evidence-backed answers, not character attacks.
The underlying tension is stark: viral marketing works, but in high-stakes biotechnology, the reputational and ethical cost of appearing evasive or dishonest is severe. A potential customer witnessing these exchanges would likely delay adoption pending resolution.